Pfizer’s Vyndaqel Success Interfering With Alnylam's Plans

Blockbuster Status In Sight For Pfizer Drug

 
• By Andrew McConaghie

Alnylam wants to emulate success of Eylea and Revlimid in amyloidosis– but Pfizer could spoil the plan.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.

More from Business

More from Scrip